Welcome!

News Feed Item

Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Glucose Control Following Standardized Meals Compared to Marketed Insulins in a Phase 2 Clinical Trial in Patients With Type 2 Diabetes

Phase 2a Clinical Trial Data Demonstrate That a Single Dose of BIOD-531 Provides Superior Glucose Control After Two Consecutive Standardized Meals Compared to Humalog (R) Mix 75/25 and Humulin(R) R U-500; Conference Call and Webcast Will Be Held in Conjun

DANBURY, CT--(Marketwired - August 11, 2014) - Biodel Inc. (NASDAQ: BIOD) announced positive preliminary results from Study 3-152, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to Humalog® Mix 75/25 and Humulin® R U-500 in patients with type 2 diabetes with moderate insulin resistance who use between 50 and 200 units of insulin per day.

Data Highlights

  • BIOD-531 was associated with superior glucose control compared to Humalog® Mix 75/25 throughout the day of observation.
  • BIOD-531 was also associated with superior glucose control compared to Humulin® R U-500.
  • BIOD-531 dosed 20 minutes after the start of the standardized breakfast also resulted in superior glucose control compared to either Humalog® Mix 75/25 or Humulin® R U-500 dosed prior to the meal. 
  • Mean visual analog scores and absolute severity scores were low for all participants, suggesting excellent injection site tolerability.

Many type 2 diabetes patients in clinical practice are treated with pre-mixed insulins, such as Humalog® Mix 75/25, in order to receive both basal and prandial insulin in a single injection. Pre-mixed insulin is commonly dosed before breakfast and before dinner and is usually used in patients who are not candidates for an intensive basal-bolus insulin regimen that would require four or more injections per day. Humulin® R U-500 is the only concentrated insulin available in the U.S. and is usually used to treat type 2 diabetes patients with severe insulin resistance who require very high doses of insulin -- typically greater than 200 units per day. 

BIOD-531 is an ultra-rapid-acting formulation of recombinant human insulin (RHI) at a concentration of 400 units/ml (U-400) combined with EDTA, citrate and magnesium sulfate. In the Phase 1 Study 3-150, the results of which were released in February 2014, BIOD-531 administered to non-diabetic, obese volunteers demonstrated ultra-rapid absorption and onset of action in comparison with Humalog® Mix 75/25 and Humulin® R U-500, and had an extended duration of action that is expected to be suitable for basal insulin needs.

The recently completed Study 3-152 was designed to test the hypothesis that a single dose of BIOD-531 would confer better postprandial glucose control for two consecutive meals compared to Humalog® Mix 75/25 when administered to type 2 diabetes patients with moderate insulin resistance. 

In Study 3-152, glucose profiles were assessed after single subcutaneous injection of 0.6 U/kg doses of the study drugs administered with a standardized breakfast on separate days in a randomized four arm cross-over sequence in which subjects received pre-meal BIOD-531, pre-meal Humalog® Mix 75/25, pre-meal Humulin® R U-500 and post meal BIOD-531. In order to assess the duration of glucose lowering, subjects received a standardized lunch at 330 minutes (5.5 hours) after breakfast dosing with no insulin administered at that time. Glucose levels were measured every five minutes during the 720 minutes (12 hours) after test insulin dosing at breakfast.

The results of the current study demonstrate that the ultra-rapid-acting profile with an extended duration of action of BIOD-531 seen in Study 3-150 may translate into clinically meaningful benefits of superior mealtime and basal coverage for type 2 diabetes patients with moderate insulin resistance.

Pre-Meal Administration of BIOD-531 vs. Pre-Meal Administration of Humalog® Mix 75/25
BIOD-531 was associated with superior glucose control compared to Humalog® Mix 75/25 throughout the day of observation. A single dose of BIOD-531 administered immediately before breakfast (pre-meal) achieved significantly lower mean glucose concentrations than did Humalog® Mix 75/25 administered immediately before breakfast. The mean glucose concentration after breakfast was 167.8 ± 10.4 mg/dl with BIOD-531 treatment compared to 205.1 ± 8.3 mg/dl with Humalog® Mix 75/25 treatment (p < 0.001). Mean glucose concentrations were also significantly improved after lunch with pre-meal BIOD-531. Over the course of the entire day of observation, pre-meal BIOD-531 was associated with an average glucose concentration of 177.8 ± 11.9 mg/dl compared to 225.1± 10.7 mg/dl with Humalog® Mix 75/25 treatment (p < 0.001). The percentage of glucose readings within the target range of 70-180 mg/dl was increased more than two-fold following BIOD-531 treatment (46.3 ± 8.4%) compared to Humalog® Mix 75/25 treatment (20.6 ± 5.9 %; p=0.002). Likewise, the post-breakfast area under the curve for the glucose excursion and the mean maximal glucose concentrations after breakfast and after lunch were significantly improved with pre-meal BIOD-531 treatment compared to Humalog® Mix 75/25 treatment.

Pre-Meal Administration of BIOD-531 vs. Pre-Meal Administration of Humulin® R U-500
BIOD-531 was also associated with superior glucose control compared to Humulin® R U-500. Mean glucose concentrations after the standardized breakfast were 167.8 ± 10.4 mg/dl with BIOD-531 treatment compared to 193.1 ± 8.3 mg/dl with Humulin® R U-500 treatment (p=0.006). Over the entire day of observation, mean glucose concentrations were 177.8 ± 11.9 mg/dl with BIOD-531 treatment compared to 197.2 ± 8.8 mg/dl with Humulin® R U-500 treatment (p=0.042). Over the course of the entire day of observation, glucose concentrations were in the target range of 70-180 mg/dl 46.3 ± 8.4% of the time with BIOD-531 treatment compared to 29.1 ± 6.1% of the time with Humulin® R U-500 treatment (p=0.032).

Post-Meal Administration of BIOD-531 vs. Pre-Meal Administration of Humalog® Mix 75/25 and Pre-Meal Administration of Humulin® R U-500
BIOD-531 dosed 20 minutes after the start of the standardized breakfast also resulted in a superior glucose control compared to either Humalog® Mix 75/25 or Humulin® R U-500 dosed prior to the meal. Mean glucose concentrations over the course of the day were 178.3 ± 11.2 mg/dl for post-meal BIOD-531 treatment compared to 225.1 ± 10.7 for pre-meal Humalog® Mix 75/25 treatment (p < 0.001). The percentage of readings within the 70-180 mg/dl target range was 46.2 ± 7.6% for post-meal BIOD-531 treatment compared to 20.6 ± 5.9% for pre-meal Humalog® Mix 75/25 treatment (p=0.003) and 29.1 ± 6.1% for pre-meal Humulin® R U-500 treatment (p=0.040).

Safety and Tolerability
Mean visual analog scores and absolute severity scores were low for all participants, suggesting excellent injection site tolerability. There were no statistically significant differences in 100 mm visual analog scores among the treatment groups. 

Dr. Alan Krasner, chief medical officer of Biodel, stated: "Many patients with type 2 diabetes who use pre-mixed insulins such as Humalog® Mix 75/25 may not achieve adequate prandial control due to the slow absorption of currently available, pre-mixed insulin formulations. These data released today validate the benefits of the ultra-rapid-acting onset of action of BIOD-531 seen in our previous Phase 1 study and clearly demonstrate the clinical superiority of this profile on post-prandial glucose control compared to Humalog® Mix 75/25 and Humulin® R U-500. The longer-term coverage provided by BIOD-531 was superior to the comparators as seen in lower glucose levels after the standardized lunch and the benefits are maintained even when dosed after the meal. This unique pharmacokinetic and pharmacodynamic profile, coupled with its high concentration and low injection volume has the potential to confer clinically significant benefits to a sub-optimally served population of patients with type 2 diabetes."

Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "BIOD-531 is a valuable asset within Biodel's expanding portfolio. It appears from these data that BIOD-531 may have utility both in the niche but rapidly growing segment of insulin resistant patients largely treated by endocrinologists and currently served by Humulin® R U-500, as well as in the much larger segment of patients currently using pre-mixed insulins and often managed by primary care physicians. We are working with the FDA to define the clinical development program that will best characterize and assess this unique formulation so that we can rapidly advance BIOD-531 into later stage clinical trials. We look forward to updating you in the fourth quarter of 2014 on the data from the ongoing Phase 2 Study 3-151 in severely insulin resistant patients and the path forward for this exciting product opportunity."

                                                                            
----------------------------------------------------------------------------
 Blood Glucose Profiles of BIOD-531 Vs. Humalog®Mix 75/25 or Humulin®R U-500
                    Following Standardized Meal Challenges                  
----------------------------------------------------------------------------
                Efficacy                                                    
    Meal        Parameter              Treatment Group Comparison           
                            ------------------------------------------------
                                        Humalog®Mix  Humulin®R              
                               BIOD-       75/25       U-500       BIOD-    
                             531Before  Before Meal Before Meal   531After  
                              Meal (A)      (B)         (C)       Meal (D)  
                                                                            
                                                                            
----------------------------------------------------------------------------
                                                                            
----------------------------------------------------------------------------
            Change BGAUC0-                                                  
After        120min(mg.min/   7140 +/-   10302 +/-    8160 +/-    7319 +/-  
 Breakfast*  dl)                962         1051        533         889     
            ----------------------------------------------------------------
            Change BGAUC0-                                                  
             330min(mg.min/  23526 +/-   33751 +/-   30158 +/-   23833 +/-  
             dl)                3054        2396        2342        3846    
            ----------------------------------------------------------------
            Avg BG0-         167.8 +/-   205.1 +/-   193.1 +/-   173.4 +/-  
             330min(mg/dl)      10.4        8.3         8.3         11.6    
            ----------------------------------------------------------------
            BGMaximum0-      192.9 +/-   233.7 +/-   212.8 +/-   195.3 +/-  
             120min(mg/dl)      12.3        12.5        7.0         10.7    
            ----------------------------------------------------------------
            Percent                                                         
             Values5-330min                                                 
             Within 70- <                                                   
             80 mg/dl Range   52.7 +/-    28.0 +/-    33.5 +/-    48.6 +/-  
             (%)                10.3        9.1         9.5         10.3    
----------------------------------------------------------------------------
                                                                            
----------------------------------------------------------------------------
After       Avg BG5-         186.3 +/-   241.9 +/-   200.7 +/-   176.4 +/-  
 Lunch**     390min(mg/dl)      15.0        15.3        11.6        14.9    
            ----------------------------------------------------------------
            BGMaximum0-      237.6 +/-   297.3 +/-   256.3 +/-   230.4 +/-  
             120min(mg/dl)      15.5        16.1        13.4        14.4    
            ----------------------------------------------------------------
            Percent                                                         
             Values0-390min                                                 
             Within 70- <                                                   
             80 mg/dl Range   41.1 +/-    13.6 +/-    25.7 +/-    43.8 +/-  
             (%)                9.1         6.4         6.9         9.8     
----------------------------------------------------------------------------
                                                                            
----------------------------------------------------------------------------
Overall     Avg Glucose0-                                                   
 Test        720min(mg/dl)   177.8 +/-   225.1 +/-   197.2 +/-   178.3 +/-  
 Period                         11.9        10.7        8.8         11.2    
            ----------------------------------------------------------------
            Percent                                                         
             Values5-720min                                                 
             Within 70- <                                                   
             80 mg/dl Range   46.3 +/-    20.6 +/-    29.1 +/-    46.2 +/-  
             (%)                8.4         5.9         6.1         7.6     
----------------------------------------------------------------------------
                                                                            
----------------------------------------------------------------------------
                                                                          
--------------------------------------------------------------------------
 Blood Glucose Profiles of BIOD-531 Vs. Humalog®Mix 75/25 or Humulin®R U- 
                 500 Following Standardized Meal Challenges               
--------------------------------------------------------------------------
                Efficacy                                                  
    Meal        Parameter             Treatment Group Comparison          
                           -----------------------------------------------
                                               P Value                    
                           -----------------------------------------------
                           (A) vs. (B) (A) vs. (C) (B) vs. (D) (C) vs. (D)
--------------------------------------------------------------------------
                                                                          
--------------------------------------------------------------------------
            Change BGAUC0-                                                
After        120min(mg.min/                                               
 Breakfast*  dl)              0.001       0.228       0.002       0.319   
            --------------------------------------------------------------
            Change BGAUC0-                                                
             330min(mg.min/                                               
             dl)              0.003       0.036       0.004       0.051   
            --------------------------------------------------------------
            Avg BG0-                                                      
             330min(mg/dl)   < 0.001      0.006       0.001       0.031   
            --------------------------------------------------------------
            BGMaximum0-                                                   
             120min(mg/dl)   < 0.001      0.050      < 0.001      0.082   
            --------------------------------------------------------------
            Percent                                                       
             Values5-330min                                               
             Within 70- <                                                 
             80 mg/dl Range                                               
             (%)              0.026       0.074       0.067       0.172   
--------------------------------------------------------------------------
                                                                          
--------------------------------------------------------------------------
After       Avg BG5-                                                      
 Lunch**     390min(mg/dl)   < 0.001      0.205      < 0.001      0.060   
            --------------------------------------------------------------
            BGMaximum0-                                                   
             120min(mg/dl)   < 0.001      0.212      < 0.001      0.101   
            --------------------------------------------------------------
            Percent                                                       
             Values0-390min                                               
             Within 70- <                                                 
             80 mg/dl Range                                               
             (%)              0.002       0.072       0.001       0.042   
--------------------------------------------------------------------------
                                                                          
--------------------------------------------------------------------------
Overall     Avg Glucose0-                                                 
 Test        720min(mg/dl)                                                
 Period                      < 0.001      0.042      < 0.001      0.058   
            --------------------------------------------------------------
            Percent                                                       
             Values5-720min                                               
             Within 70- <                                                 
             80 mg/dl Range                                               
             (%)              0.002       0.032       0.003       0.040   
--------------------------------------------------------------------------
                                                                          
--------------------------------------------------------------------------
Data presented are the Mean +/- SEM from twelve subjects randomized. One of 
these subjects discontinued after treatment with Humalog® Mix 75/25 and     
Humulin® R U-500 only. Blood glucose was measured every 5 minutes.          
BG: Blood glucose; Change BG: Change in blood glucose from baseline; AUC:   
Area under the glucose response curve                                       
*Test insulin was administered only for the breakfast meal                  
**No insulin treatment was administered at lunch (330 min after injection)  
----------------------------------------------------------------------------
                                                                            

Study Design
Study 3-152 was a single-blinded, four-arm cross-over study. Twelve subjects were randomized and 11 patients completed the study. The patients evaluated in this study were a typical population with type 2 diabetes who used between 50-200 units of insulin per day with mean age of 55 years old, mean baseline HbA1c of 9%, mean weight of 99 kg, and mean BMI of 33.5 kg/m2. Subjects were washed out of background diabetes medications (including insulins) and admitted to the research unit the evening before study drug dosing. Overnight, blood glucose concentration was stabilized at the target range of 100 ± 20 mg/dl using intravenous insulin. The intravenous insulin was discontinued no later than 15 minutes before a standardized breakfast in the morning. Each subject came in for the following four treatments administered subcutaneously on separate days assigned in a random order: (a) BIOD-531 immediately before the meal (pre-meal); (b) Humalog® Mix 75/25 pre-meal; (c) Humulin® R U-500 pre-meal; and (d) BIOD-531 twenty minutes after the start of the meal (post-meal). The dose for each session was 0.6 U/kg. After the breakfast, glucose concentrations were measured every 5 minutes throughout the day for a total of 720 minutes (12 hours) after insulin dosing. In order to assess the duration of glucose control of the test insulins, the subject received a standardized lunch 330 minutes (5.5 hours) after breakfast dosing but did not receive a lunch-time dose of insulin. Injection site toleration was assessed with a 100 mm visual analog scale and severity scores.

About BIOD-531
Biodel's concentrated insulin BIOD-531 contains 400 units per milliliter (U-400) of recombinant human insulin formulated with EDTA, citrate and magnesium sulfate. Based on its unique combination of ultra-rapid absorption with a basal duration profile, BIOD-531 may provide superior meal-time glucose control for patients using Humulin® R U-500 and pre-mixed insulins such as Humalog® Mix 75/25. Furthermore, for patients using pre-mixed prandial/basal insulins, BIOD-531 could enable patients to minimize injection volume while benefitting from the ultra-rapid onset of action.

The current unmet medical need for a concentrated ultra-rapid-acting insulin formulation exists among a subset of type 2 diabetes patients who demonstrate severe insulin resistance and require greater than 200 units of insulin daily to meet their insulin needs. Currently Eli Lilly's Humulin® R U-500 is the only concentrated insulin product on the U.S. market. Humulin® R U-500 concentrated insulin has a suboptimal pharmacokinetic and pharmacodynamic profile for prandial coverage, with a more delayed onset than U-100 regular human insulin or rapid-acting insulin analog formulations.

Eli Lilly and Novo Nordisk market preparations of human insulin or rapid-acting analog prandial insulins pre-mixed with intermediate-acting basal neutral protamine insulins in a variety of ratios such as 70/30, 75/25 and 50/50. Pre-mixes provide basal and bolus therapy with fewer injections per day. Pre-mixed prandial/basal insulins have a suboptimal pharmacokinetic and pharmacodynamic profile with a more delayed onset than prandial U-100 regular human insulin or rapid-acting insulin analog formulations. Pre-mixes represent approximately thirty percent of the more than $8 billion global rapid-acting prandial insulin market.

Conference Call and Webcast Information
Biodel's senior management will host a conference call in conjunction with Third Quarter Fiscal Year 2014 Financial Results Update on Monday, August 11, 2014 at 5:00 p.m. Eastern Daylight Time to discuss these results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing +1 (877) 407-7181 (Toll-Free US & Canada) or +1 (201) 689-8047 (International). To access the call by live audio webcast, please log on to the investor section of the company's website at www.biodel.com. An archived version of the audio webcast will be available on Biodel's website or by dialing +1 (877) 660-6853 (Toll Free US & Canada) or +1 (201) 612-7415 (International) and entering conference ID number 13588552. 

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at www.biodel.com

Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with type 1 and type 2 diabetes and our glucagon presentation that is intended to treat patients experiencing severe hypoglycemia; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin or a stable glucagon presentation; the success of our formulation development work with insulin analog-based formulations of a proprietary injectable insulin and a stable glucagon presentation; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject®), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended December 31, 2013. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

CONTACT:
John Graziano
+1-646-378-2942

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...